Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Northrop Grumman Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $76.6B | |
|---|---|---|
| Revenue (ttm) | 43.6B | |
| Net income (ttm) | 4.5B | |
| EPS (ttm) | $31.7 | |
| Shares out | 142.1M | |
| P/E (trailing) | 17.4x | |
| P/E (forward) | 17.0x | |
| Dividend | $9.88 (1.79%) | |
| Volume | 554,503 | |
| Beta | -0.11 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $35.67B | $36.60B | $39.29B | $41.03B | $41.95B | +4.1% |
| Gross profit | $7.27B | $7.47B | $39.29B | $8.36B | $8.31B | +3.4% |
| Operating income | $5.65B | $3.60B | $2.54B | $4.37B | $4.51B | -5.5% |
| Net income | $7.01B | $4.90B | $2.06B | $4.17B | $4.18B | -12.1% |
| EPS (diluted) | $43.54 | $31.47 | $13.53 | $28.34 | $29.08 | -9.6% |
| EBITDA | $8.73B | $7.68B | $2.54B | $6.84B | $7.21B | -4.7% |
| R&D | $1.10B | $1.20B | $1.20B | $1.10B | $1.10B | +0.0% |
| SG&A | $3.60B | $3.87B | $4.01B | $3.99B | $4.03B | +2.9% |
Recent company headlines from major financial publishers.
Accelerated transition from low-rate initial production to full-rate production across the B-21 Raider bomber and Sentinel ICBM programs expands segment operating margins toward 12.0%, while international allied defense demand drives sales growth at the upper bound of 7.0%, supporting an 8.5% annual EPS growth path and lifting intrinsic value toward $820.75.
Northrop Grumman executes steadily against its $109.6 billion backlog, achieving full-year 2026 sales of $43.75B-$44.25B and 2027 top-line growth of 5% to 7%. Segment operating margins expand moderately from 11.3% in 2026 to 11.4%-11.6% by 2030, absorbing the $2.1 billion capex ramp in 2027 while adjusted free cash flow expands from $3.1B-$3.5B to $3.3B-$3.7B. Discounted at a 6.68% cost of equity, this yields a central fair value of $574.82 per share.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 5.7% | $622 | $640 | $659 | $683 | $710 |
| 6.2% | $584 | $597 | $612 | $629 | $648 |
| 6.7% | $554 | $564 | $575 | $587 | $602 |
| 7.2% | $528 | $536 | $545 | $555 | $566 |
| 7.7% | $507 | $513 | $520 | $528 | $536 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |